Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	8/11/2007 2:46:59 AM
	Read Replies (1) of 946

Cell Therapeutics "market outperform" - update Friday, August 10, 2007 10:50:53 AM ET Rodman & Renshaw NEW YORK, August 10 (newratings.com) - Analyst Navdeep Jaikaria of Rodman & Renshaw reiterates his "market outperform" rating on Cell Therapeutics Inc (CTIC.NAS). The target price is set to $15 [!]. In a research note published this morning, the analyst mentions that the company has reported its 2Q07 net losses per share higher than the estimates. Cell Therapeutics's acquisition of Systems Medicine offers significant synergy potential to the former company, the analyst says. The interim RAPID results exhibit Pixantrone's potential in CHOP therapy, Rodman & Renshaw adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next